Real-Life Effectiveness and Safety of Golimumab and Its Predictors of Response in Patients with Ulcerative Colitis.
Fabrizio BossaGiuseppe BiscagliaMaria Rosa ValvanoGiuseppe CostantinoAngelo LauriaRocco ClementeConcetta FerracaneEndrit ShahiniMarco MendolaroLaurino GrossiSilvia MazzuoliAntonio RispoGiuseppe PranzoLadislava SebkovaAntonio TursiAgnese MirandaMarta PatturelliRocco SpagnuoloCristina RicciardelliCaterina SgarroPietro PaeseGaetano InserraAlessandro AzzaroneOlga NardoneWalter FriesNello BucciantiAntonino Carlo PriviteraMaria Beatrice PrincipiMaria CappelloFrancesco William GuglielmiMarco RomanoGabriele RieglerLibera FanigliuloRaffaele MelinaAngelo AndriulliPublished in: Digestive diseases and sciences (2019)
The efficacy and safety of golimumab in daily clinical practice were confirmed for the short- and long-term treatment of patients with active ulcerative colitis. Patients naïve to the anti-TNF-alpha monoclonal antibody and those with a higher total Mayo score were more likely to respond to golimumab.